This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2013 Mar 9;381(9869):782-3.

doi: 10.1016/S0140-6736(12)62038-8.

Extended adjuvant tamoxifen for breast cancer--a new era?

Trevor J Powles

PMID: 23219287
DOI: 10.1016/S0140-6736(12)62038-8

Comment

Extended adjuvant tamoxifen for breast cancer--a new era?

Trevor J Powles. Lancet. 2013.

. 2013 Mar 9;381(9869):782-3.

doi: 10.1016/S0140-6736(12)62038-8.

Author

Trevor J Powles

PMID: 23219287
DOI: 10.1016/S0140-6736(12)62038-8

No abstract available

PubMed Disclaimer

Comment on

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Davies C, et al. Lancet. 2013 Mar 9;381(9869):805-16. doi: 10.1016/S0140-6736(12)61963-1. Lancet. 2013. PMID: 23219286 Free PMC article. Clinical Trial.

Similar articles

New data refine role of adjuvant tamoxifen in early breast cancer.
[No authors listed] [No authors listed] Am J Health Syst Pharm. 1996 Jan 15;53(2):123-4. doi: 10.1093/ajhp/53.2.123. Am J Health Syst Pharm. 1996. PMID: 8653477 No abstract available.
The Atlas trial: Tamoxifen for a longer duration for early breast cancer.
Raina V. Raina V. Natl Med J India. 2013 Jan-Feb;26(1):4-5. Natl Med J India. 2013. PMID: 24066985 No abstract available.
Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer.
Machin D, Andersen KW. Machin D, et al. J Natl Cancer Inst. 1997 May 7;89(9):659-60. doi: 10.1093/jnci/89.9.659. J Natl Cancer Inst. 1997. PMID: 9150193 Clinical Trial. No abstract available.
Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M. Jahanzeb M. Clin Ther. 2007 Aug;29(8):1535-47. doi: 10.1016/j.clinthera.2007.08.013. Clin Ther. 2007. PMID: 17919537 Review.
[Effectiveness of adjuvant endocrine therapy for postoperative breast cancer patients].
Doihara H, Ogasawara Y. Doihara H, et al. Nihon Rinsho. 2007 Jun 28;65 Suppl 6:563-7. Nihon Rinsho. 2007. PMID: 17682212 Review. Japanese. No abstract available.

See all similar articles

Cited by

High-affinity tamoxifen analogues retain extensive positional disorder when bound to calmodulin.
Milanesi L, Trevitt CR, Whitehead B, Hounslow AM, Tomas S, Hosszu LLP, Hunter CA, Waltho JP. Milanesi L, et al. Magn Reson (Gott). 2021 Aug 13;2(2):629-642. doi: 10.5194/mr-2-629-2021. eCollection 2021. Magn Reson (Gott). 2021. PMID: 37905217 Free PMC article.
Bisphosphonates and breast cancer survival: a meta-analysis and trial sequential analysis of 81508 participants from 23 prospective epidemiological studies.
Liu Y, Zhao S, Zhang Y, Onwuka JU, Zhang Q, Liu X. Liu Y, et al. Aging (Albany NY). 2021 Aug 10;13(15):19835-19866. doi: 10.18632/aging.203395. Epub 2021 Aug 10. Aging (Albany NY). 2021. PMID: 34375305 Free PMC article.
Bisphosphonates and primary breast cancer risk: an updated systematic review and meta-analysis involving 963,995 women.
Liu Y, Zhang X, Sun H, Zhao S, Zhang Y, Li D, Zhang Q, Zhao Y. Liu Y, et al. Clin Epidemiol. 2019 Jul 18;11:593-603. doi: 10.2147/CLEP.S194056. eCollection 2019. Clin Epidemiol. 2019. PMID: 31410067 Free PMC article.
Tamoxifen Pharmacovigilance: Implications for Safe Use in the Future.
Antimisiaris D, Bae KG, Morton L, Gully Z. Antimisiaris D, et al. Consult Pharm. 2017 Sep 1;32(9):535-546. doi: 10.4140/TCP.n.2017.535. Consult Pharm. 2017. PMID: 28855012 Free PMC article.
TFF3 is a valuable predictive biomarker of endocrine response in metastatic breast cancer.
May FE, Westley BR. May FE, et al. Endocr Relat Cancer. 2015 Jun;22(3):465-79. doi: 10.1530/ERC-15-0129. Epub 2015 Apr 21. Endocr Relat Cancer. 2015. PMID: 25900183 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information